| HOME >> BIOLOGY >> TECHNOLOGY |
-- Eosinophils, Mast Cells and Neutrophils as Modulators of Immunity and
Injury
-- Poster Session: In Vitro Characterization of MEDI-563, a Humanized
Anti-IL-5Ralpha Monoclonal Antibody in Phase1 Clinical Trial,
publication page A602
-- Poster Session: MEDI-563, a Humanized Anti-Human IL-5R alpha Antibody
Binds to Lung Tissue Eosinophils in Asthmatic Patients, publication
page A602
-- Poster Session: A Monoclonal Anti-IL-5 Receptor (IL-5R) alpha
Antibody with Enhanced ADCC Selectively and Efficaciously Depletes
Tissue Eosinophils in IL-5 Transgenic Mice, publication page A603
The preceding presentations will occur on Tuesday, May 20 from 8:15
a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.
-- Monocytes and Macrophages in Inflammation, Immunity and Injury (Poster
Session: Role for Alveolar Macrophages in Limiting Primary RSV
Immunopathology, publication page A623) - Tuesday, May 20 from 8:15
a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.
About MedImmune
MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune's website at http://www.medimmune.com.
| SOURCE MedImmune Copyright©2008 PR Newswire. All rights reserved |